{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:16:36Z","timestamp":1794960996612,"version":"4.9.1"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Transforming growth factor-\u03b2 (TGF-\u03b2) promotes a multitude of diverse biological processes, including growth arrest of epithelial cells and proliferation of fibroblasts. Although the TGF-\u03b2 signaling pathways that promote inhibition of epithelial cell growth are well characterized, less is known about the mechanisms mediating the positive response to this growth factor. Given that TGF-\u03b2 has been shown to promote fibrotic diseases and desmoplasia, identifying the fibroblast-specific TGF-\u03b2 signaling pathways is critical. Here, we investigate the role of mammalian target of rapamycin (mTOR), a known effector of phosphatidylinositol 3-kinase (PI3K) and promoter of cell growth, in the fibroblast response to TGF-\u03b2. We show that TGF-\u03b2 activates mTOR complex 1 (mTORC1) in fibroblasts but not epithelial cells via a PI3K-Akt-TSC2\u2013dependent pathway. Rapamycin, the pharmacologic inhibitor of mTOR, prevents TGF-\u03b2\u2013mediated anchorage-independent growth without affecting TGF-\u03b2 transcriptional responses or extracellular matrix protein induction. In addition to mTORC1, we also examined the role of mTORC2 in TGF-\u03b2 action. mTORC2 promotes TGF-\u03b2\u2013induced morphologic transformation and is required for TGF-\u03b2\u2013induced Akt S473 phosphorylation but not mTORC1 activation. Interestingly, both mTOR complexes are necessary for TGF-\u03b2\u2013mediated growth in soft agar. These results define distinct and overlapping roles for mTORC1 and mTORC2 in the fibroblast response to TGF-\u03b2 and suggest that inhibitors of mTOR signaling may be useful in treating fibrotic processes, such as desmoplasia. [Cancer Res 2009;69(1):84\u201393]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-2146","type":"journal-article","created":{"date-parts":[[2008,12,31]],"date-time":"2008-12-31T08:22:49Z","timestamp":1230711769000},"page":"84-93","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Distinct Roles for Mammalian Target of Rapamycin Complexes in the Fibroblast Response to Transforming Growth Factor-\u03b2"],"prefix":"10.1158","volume":"69","author":[{"given":"Rod A.","family":"Rahimi","sequence":"first","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Thoracic Diseases Research Unit, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, Minnesota and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahefatiana","family":"Andrianifahanana","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Thoracic Diseases Research Unit, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, Minnesota and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Wilkes","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Thoracic Diseases Research Unit, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, Minnesota and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne","family":"Edens","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Thoracic Diseases Research Unit, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, Minnesota and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore J.","family":"Kottom","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Thoracic Diseases Research Unit, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, Minnesota and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Blenis","sequence":"additional","affiliation":[{"name":"2Department of Cell Biology, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Leof","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Thoracic Diseases Research Unit, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, Minnesota and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,12,31]]},"reference":[{"key":"2022061700284409800_B1","doi-asserted-by":"crossref","unstructured":"Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-\u03b2 in homeostasis and cancer. Nat Rev Cancer\u20082003; 3: 807\u201321.","DOI":"10.1038\/nrc1208"},{"key":"2022061700284409800_B2","doi-asserted-by":"crossref","unstructured":"Rahimi RA, Leof EB. TGF-\u03b2 signaling: a tale of two responses. J Cell Biochem\u20082007; 102: 593\u2013608.","DOI":"10.1002\/jcb.21501"},{"key":"2022061700284409800_B3","doi-asserted-by":"crossref","unstructured":"Wilkes MC, Mitchell H, Gulati-Penheiter S, et al. Transforming growth factor-\u03b2 activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res\u20082005; 65: 10431\u201340.","DOI":"10.1158\/0008-5472.CAN-05-1522"},{"key":"2022061700284409800_B4","doi-asserted-by":"crossref","unstructured":"Evans RA, Tian YC, Steadman R, Phillips AO. TGF-\u03b21-mediated fibroblast-myofibroblast terminal differentiation\u2014the role of smad proteins. Exp Cell Res\u20082003; 282: 90\u2013100.","DOI":"10.1016\/S0014-4827(02)00015-0"},{"key":"2022061700284409800_B5","doi-asserted-by":"crossref","unstructured":"Wilkes MC, Murphy SJ, Garamszegi N, Leof EB. Cell-type-specific activation of PAK2 by transforming growth factor \u03b2 independent of Smad2 and Smad3. Mol Cell Biol\u20082003; 23: 8878\u201389.","DOI":"10.1128\/MCB.23.23.8878-8889.2003"},{"key":"2022061700284409800_B6","doi-asserted-by":"crossref","unstructured":"Wilkes MC, Leof EB. TGF-\u03b2 activation of c-Abl is independent of receptor internalization and regulated by PI3K and PAK2 in mesenchymal cultures. J Biol Chem\u20082006; 281: 27846\u201354.","DOI":"10.1074\/jbc.M603721200"},{"key":"2022061700284409800_B7","doi-asserted-by":"crossref","unstructured":"Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol\u20082007; 127: 526\u201337.","DOI":"10.1038\/sj.jid.5700613"},{"key":"2022061700284409800_B8","doi-asserted-by":"crossref","unstructured":"Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol\u20082008; 214: 199\u2013210.","DOI":"10.1002\/path.2277"},{"key":"2022061700284409800_B9","unstructured":"Gold LI. The role for transforming growth factor-\u03b2 (TGF-\u03b2) in human cancer. Crit Rev Oncog\u20081999; 10: 303\u201360."},{"key":"2022061700284409800_B10","doi-asserted-by":"crossref","unstructured":"Korc M. Pancreatic cancer-associated stroma production. Am J Surg\u20082007; 194: S84\u20136.","DOI":"10.1016\/j.amjsurg.2007.05.004"},{"key":"2022061700284409800_B11","unstructured":"Berking C, Takemoto R, Schaider H, et al. Transforming growth factor-\u03b21 increases survival of human melanoma through stroma remodeling. Cancer Res\u20082001; 61: 8306\u201316."},{"key":"2022061700284409800_B12","doi-asserted-by":"crossref","unstructured":"Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med\u20081986; 315: 1650\u20139.","DOI":"10.1056\/NEJM198612253152606"},{"key":"2022061700284409800_B13","doi-asserted-by":"crossref","unstructured":"Leask A, Abraham DJ. TGF-\u03b2 signaling and the fibrotic response. FASEB J\u20082004; 18: 816\u201327.","DOI":"10.1096\/fj.03-1273rev"},{"key":"2022061700284409800_B14","unstructured":"Lo\u0308hr M, Schmidt C, Ringel J, et al. Transforming growth factor-\u03b21 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res\u20082001; 61: 550\u20135."},{"key":"2022061700284409800_B15","unstructured":"Lieubeau B, Garrigue L, Barbieux I, Meflah K, Gregoire M. The role of transforming growth factor \u03b21 in the fibroblastic reaction associated with rat colorectal tumor development. Cancer Res\u20081994; 54: 6526\u201332."},{"key":"2022061700284409800_B16","doi-asserted-by":"crossref","unstructured":"San Francisco IF, DeWolf WC, Peehl DM, Olumi AF. Expression of transforming growth factor-\u03b21 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer\u20082004; 112: 213\u20138.","DOI":"10.1002\/ijc.20388"},{"key":"2022061700284409800_B17","doi-asserted-by":"crossref","unstructured":"de Caestecker M. The transforming growth factor-\u03b2 superfamily of receptors. Cytokine Growth Factor Rev\u20082004; 15: 1\u201311.","DOI":"10.1016\/j.cytogfr.2003.10.004"},{"key":"2022061700284409800_B18","doi-asserted-by":"crossref","unstructured":"Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol\u20082008; 40: 383\u2013408.","DOI":"10.1016\/j.biocel.2007.09.006"},{"key":"2022061700284409800_B19","doi-asserted-by":"crossref","unstructured":"Shi Y, Massague\u0301 J. Mechanisms of TGF-\u03b2 signaling from cell membrane to the nucleus. Cell\u20082003; 113: 685\u2013700.","DOI":"10.1016\/S0092-8674(03)00432-X"},{"key":"2022061700284409800_B20","doi-asserted-by":"crossref","unstructured":"Suzuki K, Wilkes MC, Garamszegi N, Edens M, Leof EB. Transforming growth factor \u03b2 signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal-regulated kinase-dependent transcriptional responses. Cancer Res\u20082007; 67: 3673\u201382.","DOI":"10.1158\/0008-5472.CAN-06-3211"},{"key":"2022061700284409800_B21","doi-asserted-by":"crossref","unstructured":"Jacinto E, Lorberg A. TOR regulation of AGC kinases in yeast and mammals. Biochem J\u20082008; 410: 19\u201337.","DOI":"10.1042\/BJ20071518"},{"key":"2022061700284409800_B22","doi-asserted-by":"crossref","unstructured":"Potter CJ, Huang H, Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell\u20082001; 105: 357\u201368.","DOI":"10.1016\/S0092-8674(01)00333-6"},{"key":"2022061700284409800_B23","doi-asserted-by":"crossref","unstructured":"Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med\u20082004; 10: 594\u2013601.","DOI":"10.1038\/nm1052"},{"key":"2022061700284409800_B24","doi-asserted-by":"crossref","unstructured":"Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell\u20082007; 12: 9\u201322.","DOI":"10.1016\/j.ccr.2007.05.008"},{"key":"2022061700284409800_B25","doi-asserted-by":"crossref","unstructured":"Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene\u20082006; 25: 6347\u201360.","DOI":"10.1038\/sj.onc.1209885"},{"key":"2022061700284409800_B26","doi-asserted-by":"crossref","unstructured":"Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med\u20082006; 355: 1345\u201356.","DOI":"10.1056\/NEJMra055323"},{"key":"2022061700284409800_B27","doi-asserted-by":"crossref","unstructured":"Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol\u20082002; 4: 648\u201357.","DOI":"10.1038\/ncb839"},{"key":"2022061700284409800_B28","doi-asserted-by":"crossref","unstructured":"Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway. Mol Cell\u20082002; 10: 151\u201362.","DOI":"10.1016\/S1097-2765(02)00568-3"},{"key":"2022061700284409800_B29","doi-asserted-by":"crossref","unstructured":"Manning BD, Cantley LC. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase\/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans\u20082003; 31: 573\u20138.","DOI":"10.1042\/bst0310573"},{"key":"2022061700284409800_B30","doi-asserted-by":"crossref","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt\/PKB by the Rictor-mTOR complex. Science\u20082005; 307: 1098\u2013101.","DOI":"10.1126\/science.1106148"},{"key":"2022061700284409800_B31","doi-asserted-by":"crossref","unstructured":"Jacinto E, Facchinetti V, Liu D, et al. SIN1\/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell\u20082006; 127: 125\u201337.","DOI":"10.1016\/j.cell.2006.08.033"},{"key":"2022061700284409800_B32","doi-asserted-by":"crossref","unstructured":"Guertin DA, Stevens DM, Thoreen CC, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC\u03b1, but not S6K1. Dev Cell\u20082006; 11: 859\u201371.","DOI":"10.1016\/j.devcel.2006.10.007"},{"key":"2022061700284409800_B33","doi-asserted-by":"crossref","unstructured":"Sarbassov DD, Ali SM, Kim D-H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol\u20082004; 14: 1296\u2013302.","DOI":"10.1016\/j.cub.2004.06.054"},{"key":"2022061700284409800_B34","doi-asserted-by":"crossref","unstructured":"Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol\u20082004; 6: 1122\u20138.","DOI":"10.1038\/ncb1183"},{"key":"2022061700284409800_B35","doi-asserted-by":"crossref","unstructured":"Herna\u0301ndez-Negrete I, Carretero-Ortega J, Rosenfeldt H, et al. P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J Biol Chem\u20082007; 282: 23708\u201315.","DOI":"10.1074\/jbc.M703771200"},{"key":"2022061700284409800_B36","doi-asserted-by":"crossref","unstructured":"Tee AR, Anjum R, Blenis J. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase\/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem\u20082003; 278: 37288\u201396.","DOI":"10.1074\/jbc.M303257200"},{"key":"2022061700284409800_B37","doi-asserted-by":"crossref","unstructured":"Loreni F, Thomas G, Amaldi F. Transcription inhibitors stimulate translation of 5\u2032 TOP mRNAs through activation of S6 kinase and the mTOR\/FRAP signalling pathway. Eur J Biochem\u20082000; 267: 6594\u2013601.","DOI":"10.1046\/j.1432-1327.2000.01753.x"},{"key":"2022061700284409800_B38","doi-asserted-by":"crossref","unstructured":"Finlay D, Ruiz-Alcaraz AJ, Lipina C, Perrier S, Sutherland C. A temporal switch in the insulin-signalling pathway that regulates hepatic IGF-binding protein-1 gene expression. J Mol Endocrinol\u20082006; 37: 227\u201337.","DOI":"10.1677\/jme.1.02084"},{"key":"2022061700284409800_B39","doi-asserted-by":"crossref","unstructured":"Wilkes MC, Leof EB. Transforming growth factor \u03b2 activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J Biol Chem\u20082006; 281: 27846\u201354.","DOI":"10.1074\/jbc.M603721200"},{"key":"2022061700284409800_B40","doi-asserted-by":"crossref","unstructured":"Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol Cell\u20082006; 22: 159\u201368.","DOI":"10.1016\/j.molcel.2006.03.029"},{"key":"2022061700284409800_B41","doi-asserted-by":"crossref","unstructured":"Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-\u03b2 and prevents bleomycin-mediated lung fibrosis. J Clin Invest\u20082004; 114: 1303\u201316.","DOI":"10.1172\/JCI200419603"},{"key":"2022061700284409800_B42","doi-asserted-by":"crossref","unstructured":"Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF\u03b2 pathway and reduces fibrogenesis in experimental obstructive nephropathy. FASEB J\u20082005; 19: 1\u201311.","DOI":"10.1096\/fj.04-2370com"},{"key":"2022061700284409800_B43","doi-asserted-by":"crossref","unstructured":"Lamouille S, Derynck R. Cell size and invasion in TGF-\u03b2 induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol\u20082007; 178: 437\u201351.","DOI":"10.1083\/jcb.200611146"},{"key":"2022061700284409800_B44","doi-asserted-by":"crossref","unstructured":"Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol\u20082005; 56: 47\u201360.","DOI":"10.1016\/j.critrevonc.2004.09.009"},{"key":"2022061700284409800_B45","doi-asserted-by":"crossref","unstructured":"Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell\u20082006; 10: 159\u201370.","DOI":"10.1016\/j.ccr.2006.07.003"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/1\/84\/2609836\/84.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/1\/84\/2609836\/84.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:12:21Z","timestamp":1655442741000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/1\/84\/549545\/Distinct-Roles-for-Mammalian-Target-of-Rapamycin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,31]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,12,31]]},"published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-2146","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,31]]}}}